"Drug Industry" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
| Descriptor ID |
D004345
|
| MeSH Number(s) |
J01.576.655.750
|
| Concept/Terms |
Drug Industry- Drug Industry
- Industry, Pharmaceutic
- Industries, Pharmaceutic
- Pharmaceutic Industries
- Pharmaceutic Industry
- Industry, Drug
- Drug Industries
- Industries, Drug
- Industry, Pharmaceutical
- Industries, Pharmaceutical
- Pharmaceutical Industries
- Pharmaceutical Industry
|
Below are MeSH descriptors whose meaning is more general than "Drug Industry".
Below are MeSH descriptors whose meaning is more specific than "Drug Industry".
This graph shows the total number of publications written about "Drug Industry" by people in this website by year, and whether "Drug Industry" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 3 | 6 |
| 2009 | 3 | 3 | 6 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 0 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Industry" by people in Profiles.
-
Pederson T. US companies' COVID patents: Will "the saints go marching in"? FASEB J. 2021 10; 35(10):e21879.
-
Wong SL, Stain SC. Resolve the Conflict Rather than Dissolve the Relationship. Ann Surg Oncol. 2019 Aug; 26(8):2325-2326.
-
Addeo A, Weiss GJ, Gyawali B. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis. JAMA Netw Open. 2019 05 03; 2(5):e193684.
-
Gurwitz JH. Pharmaceutical Marketing at the 2018 American Geriatrics Society Annual Scientific Meeting: The Case of Noctiva and the Need for Increased Vigilance. J Am Geriatr Soc. 2018 11; 66(11):2045-2047.
-
Huang L, Sang CN, Desai MS. A Chronology for the Identification and Disclosure of Adverse Effects of Succinylcholine. J Anesth Hist. 2019 07; 5(3):65-84.
-
Shcherbakova N. Pharmaceutical industry in a global context elective course: implementation and preliminary outcomes. Int J Pharm Pract. 2018 Oct; 26(5):465-468.
-
Bridges SL, White DW, Worthing AB, Gravallese EM, O'Dell JR, Nola K, Kay J, Cohen SB. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. Arthritis Rheumatol. 2018 03; 70(3):334-344.
-
Pederson T. Pandora's Prescription: The Pharmaceutical Pricing vs. Cost Conundrum. FASEB J. 2017 11; 31(11):4661-4662.
-
Silva RMD, Chaves GC, Chaves LA, Campos MR, Luiza VL, Bertoldi AD, Ross-Degnan D, Emmerick ICM. Farm?cia Popular Program: pharmaceutical market analysis of antihypertensive acting on the renin-angiotensin system medicines. Cien Saude Colet. 2017 Aug; 22(8):2501-2512.
-
Hughes S, Wells K, McSorley P, Freeman A. Preparing individual patient data from clinical trials for sharing: the GlaxoSmithKline approach. Pharm Stat. 2014 May-Jun; 13(3):179-83.